Memory and Plasma pTau217 Refine Prognosis in Down Syndrome.

IF 7.5 1区医学 Q1 CLINICAL NEUROLOGY

Annals of Neurology Pub Date : 2026-10-02 DOI:10.1002/ana.78366

Casey R Vanderlip, Sigan L Hartley, Sharon Krinsky-McHale, Christy Hom, Adam M Brickman, Melissa E Petersen, Elizabeth Head, Craig E L Stark

引用次数: 0

Abstract

Individuals with Down syndrome (DS) are at high risk for Alzheimer's disease (AD), yet accessible tools for routine clinical screening of AD in individuals with DS remain limited. Using data from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), we show that integrating plasma pTau217 with performance on the modified cued recall task identifies a subgroup of cognitively stable individuals at markedly elevated risk of developing clinical impairment in the next 7 years. This low-burden, multimodal framework improves prognosis, supports more informed clinical management and efficient trial enrichment in Down syndrome. ANN NEUROL 2026.

查看原文本刊更多论文

记忆和血浆pTau217改善唐氏综合征的预后

唐氏综合征（DS）患者患阿尔茨海默病（AD）的风险很高，但用于唐氏综合征患者AD常规临床筛查的工具仍然有限。利用阿尔茨海默生物标志物联盟-唐氏综合征（ABC-DS）的数据，我们发现，将血浆pTau217与改良线索回忆任务的表现相结合，可以识别出一组认知稳定的个体，他们在未来7年内出现临床障碍的风险显著增加。这种低负担、多模式的框架改善了唐氏综合征的预后，支持更知情的临床管理和有效的试验充实。Ann neurol 2026。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Neurology 医学-临床神经学

CiteScore

18.00

自引率

1.80%

发文量

270

审稿时长

3-8 weeks

期刊介绍： Annals of Neurology publishes original articles with potential for high impact in understanding the pathogenesis, clinical and laboratory features, diagnosis, treatment, outcomes and science underlying diseases of the human nervous system. Articles should ideally be of broad interest to the academic neurological community rather than solely to subspecialists in a particular field. Studies involving experimental model system, including those in cell and organ cultures and animals, of direct translational relevance to the understanding of neurological disease are also encouraged.